Artiva’s AlloNK Shows 71% ACR50 Response, $300M Raise Fuels Phase 3 Trial
Analyst H.C. Wainwright raised Artiva’s price target to $35 from $15 after Phase 2a AlloNK trial showed a 71% ACR50 response in refractory rheumatoid arthritis and demonstrated good tolerability. The company secured FDA alignment for a Phase 3 registrational trial and raised $300 million through private placement.
1. Price Target Raised on Strong Phase 2a Results
H.C. Wainwright lifted its price target for Artiva from $15 to $35 following interim Phase 2a data showing a 71% ACR50 response rate in refractory rheumatoid arthritis patients and confirming good tolerability of AlloNK.
2. FDA Alignment Secured for Registrational Trial
Artiva obtained FDA agreement on a single Phase 3 registrational trial design, clearing the way to initiate late-stage testing of AlloNK in the second half of 2026, a critical milestone toward potential approval.
3. $300 Million Private Placement Completed
The company raised $300 million through a private placement with institutional investors to fund pivotal late-stage trials and support ongoing development of its cell therapy pipeline without immediate market dilution.
4. Share Price Reaction
Despite robust clinical data and capital infusion, Artiva’s shares dipped on the day as investors weighed near-term dilution from the private placement against long-term value of Phase 3 progress.